CLAIMS

1. Compounds of formula I

in which:

5

10

15

- the linker is a bivalent straight or branched C_1 - C_8 alkyl residue, C_3 - C_8 cycloalkyl, a phenylene or C_4 - C_6 heterocyclic ring;

- the G_1 and G_2 junctions, which can be the same or different, are -CO-, -CONH, -CR₂- groups in which R_2 is hydrogen or a straight C_1 - C_4 alkyl residue,

or the G₁-linker-G₂ group is the -CO- group

with the proviso that when G_1 and G_2 are both CO, or when G_1 is -CONH- and G_2 is -CO-, the linker is different from a bivalent alkyl residue.

- 2. Compounds as claimed in claim 1 wherein G₁ and G₂ are both CO or CONH.
- 3. Compounds as claimed in claim 1 or 2 in which the *linker* is a phenylene, C_5 - C_6 cycloalkylene or heterocyclic group.
- 20 4. Compounds as claimed in claim 1 or 2 wherein the *linker* is selected from bivalent straight alkyl residues having from two to six carbon atoms.
 - 5. Compounds as claimed in claim 1 or 2 in which the *linker* is selected from 1,3-ciclohexylene and 1,4-cyclohexylene.
- 6. Compounds as claimed in claim 1 or 2 in which the *linker* is selected from 1,2-, 1,3- or 1,4-phenylene.
 - 7. Compounds as claimed in claim 1 or 2 in which the *linker* is selected

from pyridyl, piperidinyl, piperazinyl linked to the G1 and G2 groups in the

14

PCT/EP2005/000987

WO 2005/075418

positions 3,5 or 2,5 or 2,6.

- compounds of formula I for antitumour, antiarthritis, 8. The antiinflammatory and antiviral use.
- Pharmaceutical compositions containing the compounds of formula I as 5 9. active ingredients in admixture with suitable carriers and/or excipients.